ES2247736T3 - Microparticulas para el transporte de sustancias farmaceuticas a traves de la mucosa y la barrera hematoencefalica. - Google Patents

Microparticulas para el transporte de sustancias farmaceuticas a traves de la mucosa y la barrera hematoencefalica.

Info

Publication number
ES2247736T3
ES2247736T3 ES98965704T ES98965704T ES2247736T3 ES 2247736 T3 ES2247736 T3 ES 2247736T3 ES 98965704 T ES98965704 T ES 98965704T ES 98965704 T ES98965704 T ES 98965704T ES 2247736 T3 ES2247736 T3 ES 2247736T3
Authority
ES
Spain
Prior art keywords
microparticles
mucosa
transport
water
pharmaceutical substances
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES98965704T
Other languages
English (en)
Inventor
Maria Rosa Gasco
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Application granted granted Critical
Publication of ES2247736T3 publication Critical patent/ES2247736T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/7036Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/23Calcitonins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51Nanocapsules; Nanoparticles
    • A61K9/5107Excipients; Inactive ingredients
    • A61K9/5123Organic compounds, e.g. fats, sugars
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00Nanotechnology
    • Y10S977/902Specified use of nanostructure
    • Y10S977/904Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/924Specified use of nanostructure for medical, immunological, body treatment, or diagnosis using nanostructure as support of dna analysis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Utilización de micropartículas compuestas de un lípido o varios lípidos y una sustancia farmacéutica seleccionada de entre péptidos, antibióticos, citoestáticos para el tratamiento de linfomas, y, opcionalmente, de un agente estabilizante seleccionado de entre el grupo formado por dipalmitoilfosfatidiletanolamina-PEG, PEG- estearato, esteres de ácidos grasos de ácido mirístico hasta ácido docosanoico con metiléter-PEG, diacilfosfatidiletanolaminas esterificadas con metiléter-PEG, y polilactatos y lactatos poliglicólicos esterificados con metiléter-PEG, para la preparación de composiciones apropiadas para ser administradas por vía oral para la absorción transmucosa de citoestáticos utilizados para el tratamiento de linfomas, y de antibióticos y péptidos con efectos sobre el sistema linfático.
ES98965704T 1997-12-01 1998-11-27 Microparticulas para el transporte de sustancias farmaceuticas a traves de la mucosa y la barrera hematoencefalica. Expired - Lifetime ES2247736T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT97MI002663A IT1296914B1 (it) 1997-12-01 1997-12-01 Composizione farmaceutica comprendente microparticelle atte al passaggio transmucosale ed al superamento della barriera

Publications (1)

Publication Number Publication Date
ES2247736T3 true ES2247736T3 (es) 2006-03-01

Family

ID=11378297

Family Applications (1)

Application Number Title Priority Date Filing Date
ES98965704T Expired - Lifetime ES2247736T3 (es) 1997-12-01 1998-11-27 Microparticulas para el transporte de sustancias farmaceuticas a traves de la mucosa y la barrera hematoencefalica.

Country Status (8)

Country Link
US (1) US6419949B1 (es)
EP (1) EP1071408B1 (es)
AT (1) ATE303799T1 (es)
AU (1) AU2155199A (es)
DE (1) DE69831511T2 (es)
ES (1) ES2247736T3 (es)
IT (1) IT1296914B1 (es)
WO (1) WO1999027918A1 (es)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1296914B1 (it) 1997-12-01 1999-08-03 Maria Rosa Gasco Composizione farmaceutica comprendente microparticelle atte al passaggio transmucosale ed al superamento della barriera
ES2211151T3 (es) 1998-08-19 2004-07-01 Skyepharma Canada Inc. Dispersiones acuosas inyectables de propofol.
US7153525B1 (en) 2000-03-22 2006-12-26 The University Of Kentucky Research Foundation Microemulsions as precursors to solid nanoparticles
AU784191B2 (en) * 2000-04-11 2006-02-16 Ibergesfer, S.L. Structure for a washbasin
DK1345597T3 (da) * 2000-12-27 2007-12-10 Ares Trading Sa Amfifile lipidanopartikler til peptid- og/eller proteininkorporering
US7763663B2 (en) 2001-12-19 2010-07-27 University Of Massachusetts Polysaccharide-containing block copolymer particles and uses thereof
AU2003233396B2 (en) * 2002-03-13 2007-05-24 Thomas Skold Water-based delivery systems
WO2003099830A2 (en) * 2002-05-24 2003-12-04 Neopharm, Inc. Cardiolipin compositions, methods of preparation and use
EA200401565A1 (ru) * 2002-05-24 2005-04-28 Неофарм, Инк. Способ получения кардиолипина или аналога кардиолипина (варианты), способ получения липосомы и композиция кардиолипина для лечения заболеваний (варианты)
US20050277611A1 (en) * 2002-10-16 2005-12-15 Neopharm, Inc. Cationic cardiolipin analoges and its use thereof
ITMI20022323A1 (it) * 2002-10-31 2004-05-01 Maria Rosa Gasco Composizioni farmaceutiche atte al trattamento di malattie oftalmiche.
US20050101605A1 (en) * 2003-11-07 2005-05-12 Ahmed Salah U. Oral liquid formulations of methotrexate
US8241670B2 (en) * 2004-04-15 2012-08-14 Chiasma Inc. Compositions capable of facilitating penetration across a biological barrier
US20070219131A1 (en) * 2004-04-15 2007-09-20 Ben-Sasson Shmuel A Compositions capable of facilitating penetration across a biological barrier
ITMI20041151A1 (it) * 2004-06-09 2004-09-09 Maria Rosa Gasco Nanoparticelle lipidiche come agenti veicolanti per acidi nucleici procedimento per la loro preparazione e loro uso
US20090180964A1 (en) * 2005-06-24 2009-07-16 Rao Papineni Transmucosal delivery of optical, spect, multimodal,drug or biological cargo laden nanoparticle(s) in small animals or humans
US9486408B2 (en) 2005-12-01 2016-11-08 University Of Massachusetts Lowell Botulinum nanoemulsions
US20070154403A1 (en) * 2006-01-05 2007-07-05 Thomas Skold Oral, Pulmonary and Transmucosal Delivery Composition
US7914988B1 (en) 2006-03-31 2011-03-29 Illumina, Inc. Gene expression profiles to predict relapse of prostate cancer
EP1867323A1 (en) * 2006-06-13 2007-12-19 Farmatron Ltd. Pharmaceutical compositions with biological barriers permeation enhancing properties
WO2008139480A2 (en) 2007-05-16 2008-11-20 Yeda Research And Development Co. Ltd. Assessment of blood-brain barrier disruption
AU2008351331B2 (en) * 2008-02-18 2014-07-17 Csir Nanoparticle carriers for drug administration and process for producing same
EP2123262A1 (en) 2008-05-20 2009-11-25 Consorzio per il Centro di Biomedica Moleculare Scrl Polyelectrolyte-encapsulated gold nanoparticles capable of crossing blood-brain barrier
RU2381506C1 (ru) * 2008-06-04 2010-02-10 Государственное образовательное учреждение высшего профессионального образования "Московский государственный медико-стоматологический университет Федерального агентства по здравоохранению и социальному развитию РФ" Способ определения динамики транспорта антибиотиков между кровью и лимфой
CA2730760A1 (en) * 2008-07-16 2010-01-21 Surmodics Pharmaceuticals, Inc. Process for preparing microparticles containing bioactive peptides
CN102176900B (zh) 2008-09-17 2017-09-26 克艾思马有限公司 药物组合物和相关的给药方法
CA2772023A1 (en) 2009-08-18 2011-02-24 Ben Gurion University Of The Negev Research And Development Authority System and method for analyzing imaging data
US10275680B2 (en) 2011-10-19 2019-04-30 Tel Hashomer Medical Research Infrastructure And Services Ltd. Magnetic resonance maps for analyzing tissue
EP2645099A1 (en) * 2012-03-30 2013-10-02 Phares Pharmaceutical Research N.V. Biorelevant compositions
EP2988668B1 (en) 2013-04-24 2019-07-24 Tel HaShomer Medical Research Infrastructure and Services Ltd. Magnetic resonance maps for analyzing tissue
JP6091721B2 (ja) * 2014-12-19 2017-03-08 積水化学工業株式会社 製剤
CN107405305B (zh) 2015-01-20 2020-12-25 泰特拉德姆集团有限责任公司 提供粘膜和皮肤屏障恢复的通用局部药物递送载体和多因子组织保湿剂
HUE071943T2 (hu) 2015-02-03 2025-10-28 Amryt Endo Inc Akromegália kezelése oktreotid orális alkalmazásával
AU2017360346B2 (en) 2016-11-21 2023-11-23 Eirion Therapeutics, Inc. Transdermal delivery of large agents
US20220096376A1 (en) * 2019-01-07 2022-03-31 Pusan National University Industry-University Cooperation Foundation Drug delivery platform using w/o/w-type triolein emulsion promotive of blood-brain barrier opening
US11141457B1 (en) 2020-12-28 2021-10-12 Amryt Endo, Inc. Oral octreotide therapy and contraceptive methods

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3421468A1 (de) * 1984-06-08 1985-12-19 Dr. Rentschler Arzneimittel Gmbh & Co, 7958 Laupheim Lipidnanopellets als traegersystem fuer arzneimittel zur peroralen anwendung
US5250236A (en) 1991-08-05 1993-10-05 Gasco Maria R Method for producing solid lipid microspheres having a narrow size distribution
DE4131562A1 (de) * 1991-09-18 1993-03-25 Medac Klinische Spezialpraep Arzneistofftraeger aus festen lipidteilchen-feste lipidnanosphaeren (sln)
DE4327063A1 (de) * 1993-08-12 1995-02-16 Kirsten Dr Westesen Ubidecarenon-Partikel mit modifizierten physikochemischen Eigenschaften
US5858398A (en) * 1994-11-03 1999-01-12 Isomed Inc. Microparticular pharmaceutical compositions
IT1292142B1 (it) * 1997-06-12 1999-01-25 Maria Rosa Gasco Composizione farmaceutica in forma di microparticelle lipidiche solide atte alla somministrazione parenterale
IT1296914B1 (it) 1997-12-01 1999-08-03 Maria Rosa Gasco Composizione farmaceutica comprendente microparticelle atte al passaggio transmucosale ed al superamento della barriera

Also Published As

Publication number Publication date
EP1071408A1 (en) 2001-01-31
IT1296914B1 (it) 1999-08-03
ATE303799T1 (de) 2005-09-15
ITMI972663A1 (it) 1999-06-01
US6419949B1 (en) 2002-07-16
DE69831511D1 (de) 2005-10-13
DE69831511T2 (de) 2006-06-14
AU2155199A (en) 1999-06-16
EP1071408B1 (en) 2005-09-07
WO1999027918A1 (en) 1999-06-10

Similar Documents

Publication Publication Date Title
ES2247736T3 (es) Microparticulas para el transporte de sustancias farmaceuticas a traves de la mucosa y la barrera hematoencefalica.
Cevc Lipid vesicles and other colloids as drug carriers on the skin
CO5170479A1 (es) Emulsion aceite en agua que comprende un agente biologicamente activo micronizado y un sistema emulsionante adecuado saturado y un mono de ester de acido acrilico. .
FR2732967B1 (fr) 1-phenylpyrazole-3-carboxamides substitues, actifs sur la neurotensine, leur preparation, les compositions pharmaceutiques en contenant
DE602005010733D1 (de) Ophthalmische emulsion mit einem immunosuppressiven mittel
DE69720759D1 (de) Gut schmeckende, fluessige, waessrige zusammensetzung fuer ein bitterschmeckendes arzneimittel
AR043272A1 (es) Una microparticula recubierta con una sustancia lipofilica que contiene una droga proteica o antigeno y formulaciones que la comprenden
UA29469C2 (uk) Ліпосомальна фармацевтична композиція для внутрішньовенного введення
BR0311867A (pt) Forma de ministração adesiva a mucosa em forma de pelìcula e uso de um extrato ou de um óleo de cannabis para a produção de uma forma de ministração adesiva a mucosa em forma de pelìcula
DZ2964A1 (fr) Diphénylurées substituées nouvelles, et compositions pharmaceutiques les contenant.
ATE172638T1 (de) Ein neues arzneimittelabgabesystem
HRP990402C1 (en) Pharmaceutical compositions for application to mucosa
MA26548A1 (fr) Compositions pharmaceutiques topiques contenant des derives de resorcinol.
CA2322805A1 (en) Fat emulsions for inhalational administration
PE109599A1 (es) Formas de dosificacion farmaceuticas solidas
DE59706140D1 (de) Einzeln dosierte, bei kontakt mit flüssigkeit schnell zerfallende, wirkstoff- und insbesondere aromastoffhaltige, folienförmige darreichungsform
DZ2461A1 (fr) Dérivés d'arylkylamines nouveaux et composition pharmaceutiques les contenant.
CO5611097A2 (es) Tableta farmaceutica
NO20024194D0 (no) Nytt selvemulgerende legemiddelavleveringssystem
EA200401397A1 (ru) Композиции-ингибиторы циклооксигеназы-2, содержащие 2-(3,5-дифторфенил)-3-[4-(метилсульфонил)фенил]-2-циклопентен-1-он или (s)-6,8-дихлор-2-(трифторметил)-2h-1-бензопиран-3-карбоновую кислоту
PT1170003E (pt) Sistema de administracao de farmacos auto-emulsionante para
WO2001005362A3 (de) Emulgatorfreie feindisperse systeme vom typ wasser-in-öl
PE20070377A1 (es) Formulaciones liquidas para la administracion controlada de derivados de bencisoxazol
AR037131A1 (es) Formulaciones de jarabe de ribavirina
BR0011864A (pt) Formulações farmacêuticas